A researcher at Charles Drew University of Medicine and Science is investigating the potential use of non-pathogenic baker's yeast as a promising, natural therapy for cancer.
Dr. Mamdooh Ghoneum presented his findings Tuesday, Feb. 2 at a special conference on "Cell Death Mechanism," sponsored by the American Association for Cancer Research (AACR) at the Omni San Diego Hotel in San Diego.
"The central focus of the meeting is cell death regulation and how to mine and exploit it for therapeutic gain," a written evaluation of the AACR special conference states. "This conference includes new complexities of cell death and cell survival, new technologies, and clinical translational aspects necessary for the evolution of new therapeutic strategies."
For more than two decades, Dr. Ghoneum has pursued a theory that cancer cells self destruct when exposed to small quantities of yeast.
In laboratory tests, Dr. Ghoneum exposed cancer cells to yeast and observed as they ingested the yeast—through a process known as phagocytosis—and then the cancer cells died. First, he investigated this phenomenon in test tubes (in vitro), introducing yeast to breast, tongue, colon, and skin cancers.
"I have no doubt that I am close to unlocking the mystery as to why cancer cells weaken to the point of destruction after eating common baker's yeast," Dr. Ghoneum said. "The cells just gravitate to the yeast. I call it fatal attraction."
In later experiments, yeast was injected inside the tumors of mice and, again, he observed a decrease in the size of the tumor mass. Then, in his most recent tests, he examined whether yeast could kill cancer cells in mice that had cancer metastasized to the lung. These tests also showed significant clearance of the cancer cells from the lung.
"We observed that when the cancer cells eat the yeast, they die," Dr. Ghoneum said.
The next step, Dr. Ghoneum said, is to conduct clinical trials to determine safety, efficacy of dosage and a method of treatment.
Born in Egypt, Dr. Ghoneum earned his Ph.D. at the University of Tokyo in 1980 and did his postdoctoral studies at UCLA, School of Medicine. Dr. Ghoneum is an internationally recognized immunologist, who is an expert in Cancer Immune Therapy. He holds patents for inventing three biological response modifiers for the treatment of cancer. He has been a researcher and professor at Charles Drew University for twenty-five years, specializing in identifying natural cures for cancer.
Dr. Ghoneum's work has been studied and duplicated by leading scientists worldwide with results published in top medical journals. His findings have been confirmed by similar studies at the U.S. Department of Health and Science, National Institute of Health (NIH).
"There is a possibility that we could find a way to treat not only the local tumor, but the tumor that has spread throughout the body," said Dr. Gus Gill, Chairman Emeritus, Department of Otolaryngology, Charles Drew University. "As a surgeon, I always thought that a better way was to try to get rid of surgery (as a necessity) when dealing with cancer."
For more information on Dr. Ghoneum's research please view the video: http://www.youtube.com/watch?v=yoWNQ6-qm94
Elia Esparza | EurekAlert!
WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf
First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences